Strides Pharma Science Limited (Star) (NSE: STAR, BSE: 532531) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹9,634 Cr, it ranks #597 by market cap among the 6,137 Indian listed companies on FinBizNet, and #12 of 63 in Pharmaceuticals. At ₹1,014.80 (as of 25 Oct 2026), the share price is 19.5% below its 52-week high of ₹1,260.90 and 32.0% above its 52-week low of ₹768.65. The share price is up 25.8% over one year and down 0.5% over three months.
| Current Price | ₹1,014.80 |
|---|---|
| Market Cap | ₹9,634 Cr |
| NSE Symbol | STAR |
| BSE Code | 532531 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 17.1 |
| Return on Equity | 20.03% |
| Return on Assets | 6.26% |
| 52-Week Range | ₹768.65 – ₹1,260.90 |
| 1-Year Price Change | +25.8% |
| 3-Month Price Change | -0.5% |
| Beta (1Y) | 0.38 |
| Dividend Yield | 0.48% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.strides.com |
| Revenue | ₹1,265 Cr |
|---|---|
| Net Profit | ₹167 Cr |
| Net Margin | 13.2% |
| EPS (Basic) | ₹17.02 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-This segment develops and manufactures pharmaceutical products. 2. Bio-Pharmaceutical Business-This segment engages in bio-pharmaceutical business. 3. Pharmaceutical Business-This segment develops and manufactures pharmaceutical products. 4. Biotech Business-This segment is involved in biotech business.
1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Strides Pharma Science Limited (Star) | ₹9,634 Cr | 17.1 | 20.03% | ₹1,265 Cr | +25.8% |
Listed by market capitalisation. Ratios are shown for context only.
Strides Pharma Science Limited (Star) is trading at ₹1,014.80, with a market capitalisation of ₹9,634 Cr.
Strides Pharma Science Limited (Star) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Strides Pharma Science Limited (Star) has a P/E of 17.1 and a return on equity of 20.03%.
Strides Pharma Science Limited (Star) is listed on the NSE under the symbol STAR and on the BSE under the scrip code 532531.
Strides Pharma Science Limited (Star)'s share price is up 25.8% over one year and down 0.5% over three months. Its 52-week range is ₹768.65 to ₹1,260.90.
In Q1 FY27, Strides Pharma Science Limited (Star) reported revenue of ₹1,265 Cr and net profit of ₹167 Cr, with basic EPS of ₹17.02 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.